Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavo-EP plus Nivolumab in Operable Locally-Regionally Advanced Melanoma
NCT04526730Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Dec 2020
- Primary completion
- Mar 2024
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 2 trial of tavokinogene telseplasmid in melanoma, sponsored by Moffitt Cancer Center. Started Dec 2020; status: completed.
02
Drugs
tavokinogene telseplasmid
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04526730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04526730.